BMCS BioTech Medics Inc (PK)

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received independent clinical testing results of its SHBAN(TM) Hand Sanitizer Solution to prove SHBAN(TM) kills the H1N1 (Swine) Influenza A virus.

An ATS Lab Study proves that SHBAN Antiseptic Hand Sanitizer caused a 96% reduction (killing) of the H1N1 virus titer using an ex-vivo skin model test method. The SHBAN Antiseptic has had other independent clinical tests which demonstrated the SHBAN ability to continue to kill virus titer, germs, fungus, mold, mildew and bacteria over various testing periods from 10 seconds to 4 hours. This study and a half dozen other studies confirms the long-lasting effectiveness of SHBAN in reducing germs, bacteria and viruses. Alcohol gel hand sanitizers only kill germs while wet about 12 to 15 seconds.

SHBAN has also been independently clinically tested to prove SHBAN is non-toxic (causing no dermatitis on human skin).

SHBAN is a bio-degradable product superior to most antiseptics because 1) SHBAN is longer lasting, SHBAN does not stop working within 15 seconds after application (like alcohol gels); 2) SHBAN is non-toxic when used as directed on humans; 3) SHBAN does NOT contain alcohol or alcohol gel which has poisoned over 22,000 children according to AAPCA; 4) SHBAN is non-staining, non-bleaching; 5) SHBAN is non-flammable; and 6) SHBAN has no harmful or toxic odors. Most hand sanitizer products cannot make all of these claims. It is essential that people buying hand sanitizers know which ones can prove that they kill the H1N1 Influenza Virus A.

SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and one US & one pending international patent. SHBAN is a trademark of BioTech Medics, Inc.

BioTech recently announced foreign distribution agreements in Turkey, Dubai and Brazil (pending). Additional distribution negotiations are in progress for Qatar, Greece, Mexico, Central America and Thailand. BioTech Medics estimates 2010 SHBAN worldwide sales at $50 million. USA distribution agreements are also pending.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Tom Wood Sr. VP Sales Phone 972-849-3782